[Adverse transfusion reactions in recipients with anti- XXXX treatment].

@entity1 @entity1445 @entity548 @entity2067
PURPOSE OF THE STUDY: @entity2067 antagonist treated @entity1 are exposed to a risk of @entity548 in case of @entity1445 leading to a need for transfusion. In order to determine the incidence of adverse transfusion reactions in these @entity1 , the reports indicating a @entity2067 antagonist treatment were analyzed. @entity1 AND METHODS: In the treated and transfused @entity1 population, the diagnosis following the adverse transfusion reactions, the incidence, the degree of severity, the blood component involved and its imputability were evaluated. RESULTS: From January 1st 2000 to December 31st 2014, 142 reports were notified in 141 @entity1 . @entity548 was observed in 102 cases (71.8%). @entity1445 of anti- @entity2067 was reported in 43 cases only (30.3%). The most frequent adverse transfusion reaction was the anti-erythrocyte alloimmunization (66 cases, 46.5%) followed by the febrile non-haemolytic reaction (37 cases, 26.1%). Most adverse reactions were non-severe (131 cases, 92.3%). The most involved blood component was the red blood cells concentrate (139 cases, 97.9%). The imputability of the blood product was certain in 39 cases only (27.5%). CONCLUSION: In @entity1 treated with @entity2067 antagonists and transfused, the anti-erythrocyte alloimmunization was the most frequent adverse transfusion reaction. @entity1445 of the @entity2067 antagonists was notified in approximately a third of cases.
